TapImmune provides clinical development clarification based on March 1 Press Release

February 07, 2016

"This agreement marks an important milestone for our darinaparsin program, as it provides validation for the compound's clinical potential as well as additional support ahead of moving into the pivotal phase later this year," said Jonathan Lewis, M.D., Ph.D., Chief Executive Officer and Chief Medical Officer of ZIOPHARM. "Solasia is a strong partner whose management and advisory team are highly experienced in the development and commercialization of products within these territories."

"We are very excited to add darinaparsin to our growing pipeline of oncology drugs. Cancer is a leading cause of death in Asia, with hematologic malignancies increasing as a subset of the total cancer incidence rate," said Steven E. Engen, President & CEO of Solasia. "Darinaparsin is well tolerated and is expected to be less toxic than arsenics commonly used in Japan, China and other territories in Asia and has demonstrated promising efficacy in hematologic cancers, including peripheral T-cell lymphoma (PTCL), a disease nearly twice as prevalent in Asia compared to the West, but for which there are very few treatment options. We look forward to working with ZIOPHARM in developing this novel drug, and to filling this growing unmet medical need in Asia."

Source: ZIOPHARM Oncology